Thrombocytopenia is a frequent issue in patients with cirrhosis undergoing various types of
procedures (e.g. liver biopsy, endoscopy and minor surgical interventions). Thrombocytopenia
< 50*10^9/L increases the risk of perioperative and postoperative bleedning and might prevent
patients with cirrhosis to undergo important procedures. Doptelet is a small molecular
trombopoetin agonist, which results in proliferation and differentiation of megakaryocytes in
the bone marrow resulting in increased levels of thrombocytes. It is given orally as a pill
and is used to increase platelet count in patients with severe thrombocytopenia (< 50*10^9/L)
and cirrhosis and thus not to normalize platelet count. This study investigates the safety
and efficacy of Doptelet in patients with cirrhosis and thrombocytopenia (< 50*10^9/L)
undergoing minor procedures like Transjugular Adjusted Liver Biopsy (TJALB) and gastroscopy.